{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:42:25Z","timestamp":1759405345244,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.vaccine.2021.11.045","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T13:36:45Z","timestamp":1637847405000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands: Two consecutive surveys in 2016\/17 and 2020"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-0564","authenticated-orcid":false,"given":"Milou","family":"Ohm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam J.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric R.A.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan J.M.","family":"Bogaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie M.","family":"van Rooijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth A.M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hester E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona R.M.","family":"van der Klis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy A.M.","family":"Berbers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.vaccine.2021.11.045_b0005","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.11.045_b0010","doi-asserted-by":"crossref","first-page":"B71","DOI":"10.1016\/j.vaccine.2009.04.070","article-title":"Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis","volume":"27","author":"Stephens","year":"2009","journal-title":"Vaccine."},{"issue":"12","key":"10.1016\/j.vaccine.2021.11.045_b0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"16","key":"10.1016\/j.vaccine.2021.11.045_b0020","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.11.045_b0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands","volume":"25","author":"de Greeff","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.11.045_b0030","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am."},{"key":"10.1016\/j.vaccine.2021.11.045_b0035","unstructured":"Schurink-van 't Klooster T, de Melker H. The National Immunisation Programme in the Netherlands: Surveillance and developments in 2019\u20132020. Het Rijksvaccinatieprogramma in Nederland: Surveillance en ontwikkelingen in 2019\u20132020: Rijksinstituut voor Volksgezondheid en Milieu RIVM; 2020."},{"key":"10.1016\/j.vaccine.2021.11.045_b0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2807\/1560-7917.ES.2018.23.16.18-00158","article-title":"Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018","volume":"23","author":"Knol","year":"2018","journal-title":"Eurosurveillance."},{"issue":"10","key":"10.1016\/j.vaccine.2021.11.045_b0045","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/S2468-2667(17)30157-3","article-title":"Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study","volume":"2","author":"Knol","year":"2017","journal-title":"Lancet Public Health."},{"issue":"34","key":"10.1016\/j.vaccine.2021.11.045_b0050","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1016\/j.vaccine.2020.05.087","article-title":"MenACWY vaccination campaign for adolescents in the Netherlands: uptake and its determinants","volume":"38","author":"de Oliveira Bressane Lima","year":"2020","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.11.045_b0055","article-title":"Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study","author":"Ohm","year":"2021","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2021.11.045_b0060","unstructured":"The immunological basis for immunization series: module 15: meningococcal disease. Geneva: World Health Organization; Update 2020."},{"issue":"3","key":"10.1016\/j.vaccine.2021.11.045_b0065","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tim.2006.01.007","article-title":"Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines","volume":"14","author":"Heyderman","year":"2006","journal-title":"Trends Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.11.045_b0070","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4019-y","article-title":"Third national biobank for population-based seroprevalence studies in the Netherlands, including the Caribbean Netherlands","volume":"19","author":"Verberk","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2021.11.045_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab264","article-title":"Associations between measures of social distancing and severe acute respiratory syndrome coronavirus 2 seropositivity: a nationwide population-based study in the Netherlands","author":"Vos","year":"2021","journal-title":"Clin Infect Dis."},{"issue":"6","key":"10.1016\/j.vaccine.2021.11.045_b0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/jech-2020-215678","article-title":"Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave","volume":"75","author":"Vos","year":"2021","journal-title":"J Epidemiol Community Health"},{"issue":"3","key":"10.1016\/j.vaccine.2021.11.045_b0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/CVI.00364-08","article-title":"Simultaneous detection of Haemophilus influenzae type b polysaccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay","volume":"16","author":"de Voer","year":"2009","journal-title":"Clin Vaccine Immunol: CVI."},{"issue":"8","key":"10.1016\/j.vaccine.2021.11.045_b0090","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/CVI.00478-07","article-title":"Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides","volume":"15","author":"de Voer","year":"2008","journal-title":"Clin Vaccine Immunol: CVI."},{"key":"10.1016\/j.vaccine.2021.11.045_b0095","first-page":"272","article-title":"Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135","volume":"11","author":"Lal","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.11.045_b0100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol."},{"issue":"3","key":"10.1016\/j.vaccine.2021.11.045_b0105","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Burns","year":"2001","journal-title":"Infect Immun"},{"issue":"17-18","key":"10.1016\/j.vaccine.2021.11.045_b0110","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.11.045_b0115","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2021.11.045_b0120","doi-asserted-by":"crossref","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","article-title":"Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine","volume":"5","author":"de Voer","year":"2010","journal-title":"PloS one."},{"key":"10.1016\/j.vaccine.2021.11.045_b0125","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1128\/iai.8.6.896-900.1973","article-title":"Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A","volume":"8","author":"Myerowitz","year":"1973","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2021.11.045_b0130","doi-asserted-by":"crossref","first-page":"e0250103","DOI":"10.1371\/journal.pone.0250103","article-title":"Seroprevalence of meningococcal serogroup C bactericidal antibodies in the Portuguese population, a decade after vaccine introduction in the National Immunisation Programme","volume":"16","author":"Gon\u00e7alves","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2021.11.045_b0135","doi-asserted-by":"crossref","unstructured":"Findlow H, Campbell H, Lucidarme J, Andrews N, Linley E, Ladhani S, et al. Serogroup C Neisseria meningitidis disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998\/99 to 2015\/16. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2019;24.","DOI":"10.2807\/1560-7917.ES.2019.24.1.1700818"},{"key":"10.1016\/j.vaccine.2021.11.045_b0140","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 19 99\u201320 00 and response to a booster: a phase 4 clinical trial","volume":"50","author":"Perrett","year":"2010","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am."},{"issue":"1","key":"10.1016\/j.vaccine.2021.11.045_b0145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol: CVI."},{"issue":"20-22","key":"10.1016\/j.vaccine.2021.11.045_b0150","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1016\/S0264-410X(00)00528-4","article-title":"Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age","volume":"19","author":"Bramley","year":"2001","journal-title":"Vaccine."},{"issue":"apr01 16","key":"10.1016\/j.vaccine.2021.11.045_b0155","doi-asserted-by":"crossref","first-page":"h1554","DOI":"10.1136\/bmj.h1554","article-title":"Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial","volume":"350","author":"Pace","year":"2015","journal-title":"BMJ"},{"issue":"41","key":"10.1016\/j.vaccine.2021.11.045_b0160","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.vaccine.2013.07.083","article-title":"Effectiveness of meningococcal serogroup C vaccine programmes","volume":"31","author":"Borrow","year":"2013","journal-title":"Vaccine."},{"issue":"5","key":"10.1016\/j.vaccine.2021.11.045_b0165","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol: CVI."},{"issue":"3","key":"10.1016\/j.vaccine.2021.11.045_b0170","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3201\/eid2503.181574","article-title":"University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013\u20132018","volume":"25","author":"Soeters","year":"2019","journal-title":"Emerg Infect Dis J."},{"issue":"31","key":"10.1016\/j.vaccine.2021.11.045_b0175","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1016\/j.vaccine.2018.06.030","article-title":"Prevention of meningococcal disease at mass gatherings: Lessons from the Hajj and Umrah","volume":"36","author":"Yezli","year":"2018","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.11.045_b0180","unstructured":"Schurink-van 't Klooster T, de Melker H. The National Immunisation Programme in the Netherlands: Surveillance and developments in 2018\u20132019. Het Rijksvaccinatieprogramma in Nederland: Surveillance en ontwikkelingen in 2018\u20132019: Rijksinstituut voor Volksgezondheid en Milieu RIVM."},{"key":"10.1016\/j.vaccine.2021.11.045_b0185","doi-asserted-by":"crossref","unstructured":"Woudenberg T, van Binnendijk RS, Sanders EA, Wallinga J, de Melker HE, Ruijs WL, et al. Large measles epidemic in the Netherlands, May 2013 to March 2014: changing epidemiology. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2017;22.","DOI":"10.2807\/1560-7917.ES.2017.22.3.30443"},{"issue":"11-12","key":"10.1016\/j.vaccine.2021.11.045_b0190","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0264-410X(00)00333-9","article-title":"Development of natural immunity to Neisseria meningitidis","volume":"19","author":"Pollard","year":"2001","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.11.045_b0195","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2021.11.045_b0200","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/CDLI.5.4.479-485.1998","article-title":"A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses","volume":"5","author":"Granoff","year":"1998","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2021.11.045_b0205","doi-asserted-by":"crossref","unstructured":"Miellet WR, Mariman R, Pluister G, de Jong LJ, Grift I, Wijkstra S, et al. Detection of <em>Neisseria meningitidis<\/em> in Saliva and Oropharyngeal Samples from College Students. bioRxiv. 2021:2021.06.09.447670.","DOI":"10.1101\/2021.06.09.447670"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21015012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21015012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:06:31Z","timestamp":1759403191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21015012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0264410X21015012"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seroprevalence of meningococcal ACWY antibodies across the population in the Netherlands: Two consecutive surveys in 2016\/17 and 2020","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}